糖耐量减低患者应用吡格列酮治疗前后血清C反应蛋白的变化  

Changes in C-reactive Protein in Patients with Impaired Glucose Tolerance Treated with Pioglitazone

作　　者：何东华[1] 叶继峰[1] 汪学静[1] 

机构地区：[1]聊城市第二人民医院内分泌科,山东临清252601

出　　处：《医学综述》2008年第3期472-474,共3页Medical Recapitulate

摘　　要：目的观察盐酸吡格列酮治疗糖耐量减低(IGT)前后血清高敏C反应蛋白(hsCRP)的变化及其影响因素,探讨糖脂代谢与炎性因子的关系。方法采用随机平行对照方法将86例IGT患者随机分为盐酸吡格列酮组与对照组,进行为期12周的临床观察。结果吡格列酮治疗后患者hsCRP水平明显下降(P<0.01),而对照组无变化。结论IGT患者高血糖状态、胰岛素抵抗(IR)与炎症关系密切,吡格列酮治疗在改善糖脂代谢的同时,还具有明显的抗炎作用,使hsCRP水平明显下降。Objective To observe the changes in serum high sensitivity C-reactive protein（hsCRP） in patients with impaired glucose tolerance after treatment with pioglitazone and investigate the relationship between inflammatory factors and metabolism of glucose and lipid. Methods A 12-week randomized, controlled study was performed to compare the effects of placebo and pioglitazone in 86 patients with IGT. Results A significant reduction in hsCRP level was observed during teatment with pioglitazone（ P 〈 0.01 ）, in the placebo treated patients the hsCRP level varied non-signifieantlyConclusion There is a close relationship among hyperglycemia, insulin resistance, and inflammation in patients with IGT,pioglitazoue not only has obvious anti-inflammatory actiou,but also can decrease the level of hsCRP besides the effect improving the glyeolipid metabolism.

关 键 词：糖尿病 吡格列酮 糖耐量减低 C反应蛋白 

分 类 号：R587.1[医药卫生—内分泌]